Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation

Pharmaceutical Research

Volumn 20, Issue 9, 2003, Pages 1325-1336

  Chi, Eva Y ^a   Krishnan, Sampathkumar ^b   Randolph, Theodore W ^a   Carpenter, John F ^c  

^a UCB 450   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Conformational stability; Denaturation; Formulation; Pharmaceuticals; Second virial coefficient

Indexed keywords

DEOXYHEMOGLOBIN; INSULIN; INTERLEUKIN 1BETA; LOW MOLECULAR WEIGHT PLASMINOGEN ACTIVATOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT CONSENSUS INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; RELAXIN; RIBONUCLEASE A; STREPTOKINASE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; BIOTECHNOLOGY; DRUG FORMULATION; DRUG STORAGE; INSTRUMENT STERILIZATION; LIFESPAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW;

DRUG STABILITY; DRUG STORAGE; HYDROGEN-ION CONCENTRATION; PHARMACEUTICAL SOLUTIONS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEINS; SOLVENTS; SURFACE-ACTIVE AGENTS; TEMPERATURE; WATER;

EID: 0141567459     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025771421906     Document Type: Review

References (111)

1. H. Wu. Studies on the denaturation of proteins, XIII. A theory of denaturation. Chinese J. Physiol. 5:321-344 (1931).
2. J. T. Edsall. Hsien Wu and the first theory of protein denaturation (1931). Adv. Protein Chem. 46:1-5 (1995).
3. R. Lumry and H. Eyring. Conformation changes of proteins. J. Phys. Chem. 58:110-120 (1954).
4. PhRMA. The promise of breakthroughs in biotechnology is bright with 369 biotechnology medicines with testing. http://www.phrma.org. 2000.
5. J. L. Cleland, M. F. Powell, and S. J. Shire. The development of stable protein formulations - a close look at protein aggregation, deamidation and oxidation. Crit. Rev. Ther. Drug 10:307-377 (1993).
6. M. C. Manning, K. Patel, and R. T. Borchardt. Stability of protein pharmaceuticals. Pharm. Res. 6:903-918 (1989).
7. C. Goolcharran, M. Khossravi, and R. T. Borchardt. Chemical pathways of peptide and protein degradation. In S. Frokjaer and L. Hovgaards (eds.), Pharmaceutical Formulation and Development of Peptides and Proteins, Taylor and Francis, London, 2000, pp. 70-88.
8. J. Brange. Physical stability of proteins. In S. Frokjaer and L. Hovgaards (eds.), Pharmaceutical Formulation and Development of Peptides and Proteins, Taylor and Francis, London, 2000, pp. 89-112.
9. D. B. Volkin and C. R. Middaugh. In T. J. Ahern and M. C. Mannings (eds.), Stability of Protein Pharmaceuticals. Part A: Chemical and Physical Pathways of Protein Degradation, Plenum Press, New York, 1992, p. 215.
10. T. W. Randolph and L. S. Jones. Surfactant-protein interactions. In J. F. Carpenter and M. C. Mannings (eds.), Rational Design of Stable Protein Formulations, Theory and Practice, Kluwer Academic/Plenum Publishers, New York, 2002, p. 198.
11. A. C. Dong, S. J. Prestrelski, S. D. Allison, and J. F. Carpenter. Infrared spectroscopic studies of lyophilization-induced and temperature-induced protein aggregation. J. Pharm. Sci. 84:415-424 (1995).
12. A. Wang, A. D. Robertson, and D. W. Bolen. Effects of a naturally occurring compatible osmolyte on the internal dynamics of ribonuclease-a. Biochemistry 34:15096-15104 (1995).
13. J. F. Carpenter, B. S. Kendrick, B. S. Chang, M. C. Manning, and T. W. Randolph. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 309:236-255 (1999).
14. A. L. Fink. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold. Des. 3:R9-R23 (1998).
15. Y.-S. Kim, S. P. Cape, E. Y. Chi, R. Raffen, P. Wilkins-Stevens, F. J. Stevens, M. C. Manning, T. W. Randolph, A. Solomon, and J. F. Carpenter. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J. Biol. Chem. 276:1626-1633 (2001).
16. Y. F. Maa and C. C. Hsu. Aggregation of recombinant human growth hormone induced by phenolic compounds. Int. J. Pharm. 140:155-168 (1996).
17. S. Krishnan, E. Y. Chi, J. N. Webb, B. S. Chang, D. Shan, M. Goldenberg, M. C. Manning, T. W. Randolph, and J. F. Carpenter. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41:6422-6431 (2002).
18. B. S. Kendrick, J. L. Cleland, X. Lam, T. Nguyen, T. W. Randolph, M. C. Manning, and J. F. Carpenter. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J. Pharm. Sci. 87:1069-1076 (1998).
19. Y.-S. Kim, J. S. Wall, J. Meyer, C. Murphy, T. W. Randolph, M. C. Manning, and J. F. Carpenter. Thermodynamic modulation of light chain amyloid fibril formation. J. Biol. Chem. 276:1570-1574 (2000).
20. E. Y. Chi, S. Krishnan, B. S. Kendrick, B. S. Chang, J. F. Carpenter, and T. W. Randolph. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci. 12:903-913 (2003).
21. K. A. Dill. Dominant forces in protein folding. Biochemistry 29: 7133-7155 (1990).
22. C. N. Pace, B. A. Shirley, M. McNutt, and K. Gajiwala. Forces contributing to the conformational stability of proteins. FASEB J. 10:75-83 (1996).
23. R. Jaenicke. In R. Huber and E. L. Winnackers (eds.), Protein Structure and Protein Engineering, Springer Verlag, Berlin, 1988, pp. 16-36.
24. R. Jaenicke and R. Rudolph. In T. E. Creightons (ed.), Protein Structure: A Practical Approach, IRL Press, Oxford, 1989, pp. 191-223.
25. R. Jaenicke. Protein folding: Local structures, domains, subunits, and assemblies. Biochemistry 30:3147-3161 (1991).
26. J. Israelachvili. Intermolecular and Surface Forces, Academic Press, San Diego, California, 1992.
27. G. Graziano, F. Catanzano, A. Riccio, and G. Barone. A reassessment of the molecular origin of cold denaturation. J. Biochem. (Tokyo) 122:395-401 (1997).
28. N. T. Southall, K. A. Dill, and A. D. J. Haymet. A view of the hydrophobic effect. J. Phys. Chem. B 106:521-533 (2002).
29. P. L. Privalov. Cold denaturation of proteins. Crit. Rev. Biochem. Mol. Biol. 25:281-305 (1990).
30. P. L. Privalov and S. J. Gill. Stability of protein structure and hydrophobic interaction. Adv. Protein Chem. 39:191-234 (1988).
31. C. N. Pace. Polar group burial contributes more to protein stability than nonpolar group burial. Biochem. 40:310-313 (2001).
32. R. L. Remmele, S. D. Bhat, D. H. Phan, and W. R. Gombotz. Minimization of recombinant human flt3 ligand aggregation at the t-m plateau: A matter of thermal reversibility. Biochem. 38:5241-5247 (1999).
33. A. I. Azuaga, C. M. Dobson, P. L. Mateo, and F. Conejero-Lara. Unfolding and aggregation during the thermal denaturation of streptokinase. Eur. J. Biochem. 269:4121-4133 (2002).
34. B. L. Chen, T. Arakawa, E. Hsu, L. O. Narhi, T. J. Tressel, and S. L. Chien. Strategies to suppress aggregation of recombinant keratinocyte growth-factor during liquid formulation development. J. Pharm. Sci. 83: 1657-1661 (1994).
35. B. L. Chen, T. Arakawa, C. F. Morris, W. C. Kenney, C. M. Wells, and C. G. Pitt. Aggregation pathway of recombinant human keratinocyte growth- factor and its stabilization. Pharm. Res. 11:1581-1587 (1994).
36. A. Y. Ip, T. Arakawa, H. Silvers, C. M. Ransone, and R. W. Niven. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J. Pharm. Sci. 84:1210-1214 (1995).
37. M. G. Mulkerrin and R. Wetzel. pH-dependence of the reversible and irreversible thermal-denaturation of gamma-interferons. Biochem. 28:6556-6561 (1989).
38. A. M. Tsai, J. H. van Zanten, and M. J. Betenbaugh. II. Electrostatic effect in the aggregation of heat-denatured RNase a and implications for protein additive design. Biotechnol. Bioeng. 59:281-285 (1998).
39. A. M. Tsai, J. H. van Zanten, and M. J. Betenbaugh. I. Study of protein aggregation due to heat denaturation: A structural approach using circular dichroism spectroscopy, nuclear magnetic resonance, and static light scattering. Biotechnol. Bioeng. 59:273-280 (1998).
40. P. Atkins. Physical Chemistry, W. H. Freeman and Company, New York, 1994.
41. A. Fatouros, T. Osterberg, and M. Mikaelsson. Recombinant factor VIII SQ - influence of oxygen, metal ions, ph and ionic strength on its stability in aqueous solution. Int. J. Pharm. 155:121-131 (1997).
42. M. Vrkljan, T. M. Foster, M. E. Powers, J. Henkin, W. R. Porter, H. Staack, J. F. Carpenter, and M. C. Manning. Thermal-stability of low-molecular-weight urokinase during heat-treatment.2. Effect of polymeric additives. Pharm. Res. 11:1004-1008 (1994).
43. T. H. Nguyen and S. J. Shire. Stability and characterization of recombinant human relaxin. In R. Pearlman and Y. J. Wangs (eds.), Formulation, Characterization, and Stability of Protein Drugs, Plenum Press, New York, 1996, pp. 247-211.
44. B. A. Kerwin, M. J. Akers, I. Apostol, C. Moore-Einsel, J. E. Etter, E. Hess, J. Lippincott, J. Levine, A. J. Mathews, P. Revilla-Sharp, R. Schubert, and D. L. Looker. Acute and long-term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications. J. Pharm. Sci. 88:79-88 (1999).
45. L. C. Gu, E. A. Erdos, H. S. Chiang, T. Calderwood, K. Tsai, G. C. Visor, J. Duffy, W. C. Hsu, and L. C. Foster. Stability of interleukin-1-beta (IL-1-gamma) in aqueous solution - analytical methods, kinetics, products, and solution formulation implications. Pharm. Res. 8:485-490 (1991).
46. M. W. Townsend and P. P. Deluca. Stability of ribonuclease-a in solution and the freeze-dried state. J. Pharm. Sci. 79:1083-1086 (1990).
47. L. Nielsen, R. Khurana, A. Coats, S. Frokjaer, J. Brange, S. Vyas, V. N. Uversky, and A. L. Fink. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 40:6036-6046 (2001).
48. K. Takano, K. Tsuchimori, Y. Yamagata, and K. Yutani. Contribution of salt bridges near the surface of a protein to the conformational stability. Biochemistry 39:12375-12381 (2000).
49. G. R. Grimsley, K. L. Shaw, L. R. Fee, R. W. Alston, B. M. P. Huyghues-Despointes, R. L. Thurlkill, J. M. Scholtz, and C. N. Pace. Increasing protein stability by altering long-range coulombic interactions. Protein Sci. 8:1843-1849 (1999).
50. A. Striolo, D. Bratko, J. Z. Wu, N. Elvassore, H. W. Blanch, and J. M. Prausnitz. Forces between aqueous nonuniformly charged colloids from molecular simulation. J. Chem. Phys. 116:7733-7743 (2002).
51. S. N. Timasheff. Control of protein stability and reactions by weakly interacting cosolvents: The simplicity of the complicated. Adv. Protein Chem. 51:355-432 (1998).
52. P. K. Tsai, D. B. Volkin, J. M. Dabora, K. C. Thompson, M. W. Bruner, J. O. Gress, B. Matuszewska, M. Keogan, J. V. Bondi, and C. R. Middaugh. Formulation design of acidic fibroblast growth-factor. Pharm. Res. 10:649-659 (1993).
53. B. C. Cunningham, M. G. Mulkerrin, and J. A. Wells. Dimerization of human growth-hormone by zinc. Science 253:545-548 (1991).
54. P. R. Davis-Searles, A. J. Saunders, D. A. Erie, D. J. Winzor, and G. J. Pielak. Interpreting the effects of small uncharged solutes on protein-folding equilibria. Annu. Rev. Biophys. Biomol. Struct. 30:271-306 (2001).
55. M. G. Cacace, E. M. Landau, and J. J. Ramsden. The hofmeister series: Salt and solvent effects on interfacial phenomena. Q. Rev. Biophys. 30:241-277 (1997).
56. T. Arakawa and S. N. Timasheff. Stabilization of protein-structure by sugars. Biochemistry 21:6536-6544 (1982).
57. J. C. Lee and S. N. Timasheff. The stabilization of proteins by sucrose. J. Biol. Chem. 256:7193-7201 (1981).
58. R. Sousa. Use of glycerol, polyols, and other protein structure stabilizing agents in protein crystallization. Acta Cryst. D51:271-277 (1995).
59. B. A. Kerwin, M. C. Heller, S. H. Levin, and T. W. Randolph. Effects of tween 80 and sucrose on acute short-term stability and long-term storage at -20 degrees C of a recombinant hemoglobin. J. Pharm. Sci. 87:1062-1068 (1998).
60. S. D. Webb, J. L. Cleland, J. F. Carpenter, and T. W. Randolph. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: Slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J. Pharm. Sci. 91:543-558 (2002).
61. B. S. Kendrick, J. F. Carpenter, J. L. Cleland, and T. W. Randolph. A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc. Natl. Acad. Sci. USA 95:14142-14146 (1998).
62. B. L. Chen and T. Arakawa. Stabilization of recombinant human keratinocyte growth factor by osmolytes and salts. J. Pharm. Sci. 85:419-422 (1996).
63. B. S. Kendrick, B. S. Chang, T. Arakawa, B. Peterson, T. W. Randolph, M. C. Manning, and J. F. Carpenter. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc. Natl. Acad. Sci. USA 94:11917-11922 (1997).
64. T. Arakawa and S. N. Timasheff. Mechanism of protein salting in and salting out by divalent-cation salts - balance between hydration and salt binding. Biochemistry 23:5912-5923 (1984).
65. D. S. MacLean, Q. S. Qian, and C. R. Middaugh. Stabilization of proteins by low molecular weight multi-ions. J. Pharm. Sci. 91:2220-2229 (2002).
66. C. Nishimura, V. N. Uversky, and A. L. Fink. Effect of salts on the stability and folding of staphylococcal nuclease. Biochem. 40:2113-2128 (2001).
67. R. A. Curtis, J. Ulrich, A. Montaser, J. M. Prausnitz, and H. W. Blanch. Protein-protein interactions in concentrated electrolyte solutions - hofmeister-series effects. Biotechnol. Bioeng. 79:367-380 (2002).
68. M. Yamasaki, H. Yano, and K. Aoki. Differential scanning calorimetric studies on bovine serum- albumin.2. Effects of neutral salts and urea. Int. J. Biol. Macromol. 13:322-328 (1991).
69. B. L. Chen, X. R. Wu, S. J. Babuka, and M. Hora. Solubility of recombinant human tissue factor pathway inhibitor. J. Pharm. Sci. 88:881-888 (1999).
70. M. Z. Zhang, J. Wen, T. Arakawa, and S. J. Prestrelski. A new strategy for enhancing the stability of lyophilized protein - the effect of the reconstitution medium on keratinocyte growth-factor. Pharm. Res. 12:1447-1452 (1995).
71. T. Arakawa. Hydration as a major factor in preferential solvent-protein interactions. Cryst. Growth Des. 2:549-551 (2002).
72. R. L. Remmele, N. S. Nightlinger, S. Srinivasan, and W. R. Gombotz. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm. Res. 15:200-208 (1998).
73. J. Fransson, D. Hallen, and E. FlorinRobertsson. Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm. Res. 14:606-612 (1997).
74. X. M. Lam, T. W. Patapoff, and T. H. Nguyen. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm. Res. 14:725-729 (1997).
75. L. S. Jones, N. B. Bam, and T. W. Randolph. Surfactant-stabilized protein formulations: A review of protein-surfactants interactions and novel analytical methodologies. In Z. Shahrokhs (ed.), Therapeutic Protein and Peptide Formulation and Delivery, American Chemical Society, Washington, DC, 1997, pp. 206-222.
76. N. B. Bam, J. L. Cleland, J. Yang, M. C. Manning, J. F. Carpenter, R. F. Kelley, and T. W. Randolph. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J. Pharm. Sci. 87:1554-1559 (1998).
77. N. B. Bam, J. L. Cleland, and T. W. Randolph. Molten globule intermediate of recombinant human growth hormone: Stabilization with surfactants. Biotechnol. Prog. 12:801-809 (1996).
78. M. N. Jones. Protein-surfactant interactions. In S. Magdassis (eds.), Surface Activity of Proteins: Chemical and Physicochemical Modifications, Marcel Dekker, New York, 1996, p. 327.
79. A. L. Fink, L. J. Calciano, Y. Goto, T. Kurotsu, and D. R. Palleros. Classification of acid denaturation of proteins - intermediates and unfolded states. Biochemistry 33:12504-12511 (1994).
80. R. Carrotta, R. Bauer, R. Waninge, and C. Rischel. Conformational characterization of oligomeric intermediates and aggregates in beta-lactoglobulin heat aggregation. Protein Sci. 10:1312-1318 (2001).
81. I. Gomez-Orellana, B. Variano, J. Miura-Fraboni, S. Milstein, and D. R. Paton. Thermodynamic characterization of an intermediate state of human growth hormone. Protein Sci. 7:1352-1358 (1998).
82. M. A. Speed, T. Morshead, and D. I. C. Wang, and J. King. Conformation of p22 tailspike folding and aggregation intermediates probed by monoclonal antibodies. Protein Sci. 6:99-108 (1997).
83. J. King. C. HaasePettingell, A. S. Robinson, M. Speed, and A. Mitraki. Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates. FASEB J. 10:57-66 (1996).
84. D. Y. Kim and M. H. Yu. Folding pathway of human alpha(1)-antitrypsin: Characterization of an intermediate that is active but prone to aggregation. Biochem. Biophys. Res. Commun. 226:378-384 (1996).
85. R. Khurana, J. R. Gillespie, A. Talapatra, L. J. Minert, C. Ionescu-Zanetti, I. Millett, and A. L. Fink. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40:3525-3535 (2001).
86. A. O. Grillo, K. L. T. Edwards, R. S. Kashi, K. M. Shipley, L. Hu, M. J. Besman, and C. R. Middaugh. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 40:586-595 (2001).
87. J. N. Webb, S. D. Webb, J. L. Cleland, J. F. Carpenter, and T. W. Randolph. Partial molar volume, surface area, hydration changes for equilibrium unfolding and formation of aggregation transition state: High-pressure and cosolute studies on recombinant human ifn-γ. Proc. Natl. Acad. Sci. USA 98:7259-7264 (2001).
88. J. M. Friedman. Time-resolved resonance raman-spectroscopy as probe of structure, dynamics, and reactivity in hemoglobin. Methods Enzymol. 232:205-231 (1994).
89. A. D. Barksdale, D. G. Knox, and A. Rosenberg. Structure dynamics of proteins by hydrogen-exchange methods. Biophys. J. 32:619-621 (1980).
90. J. M. Sanchez-Ruiz. Theoretical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophy. J. 61:921-935 (1992).
91. S. E. Zale and A. M. Klibanov. On the role of reversible denaturation (unfolding) in the irreversible thermal inactivation of enzymes. Biotechnol. Bioeng. 25:2221-2230 (1983).
92. S. N. Timasheff and T. Arakawa. Mechanism of protein precipitation and stabilization by co-solvents. J. Cryst. Growth 90:39-46 (1988).
93. A. George, Y. Chiang, B. Guo, A. Arabshahi, Z. Cai, and W. W. Wilson. Second virial coefficient as predictor in protein crystal growth. Methods Enzymol. 276:100-110 (1997).
94. D. Rosenbaum, P. C. Zamora, and C. F. Zukoski. Phase behavior of small attractive colloidal particles. Phys. Rev. Lett. 76:150-153 (1996).
95. C. Haas and J. Drenth. Understanding protein crystallization on the basis of the phase diagram. J. Cryst. Growth 196:388-394 (1999).
96. R. A. Curtis, H. W. Blanch, and J. M. Prausnitz. Calculation of phase diagrams for aqueous protein solutions. J. Phys. Chem. B 105:2445-2452 (2001).
97. M. Farnum and C. Zukoski. Effect of glycerol on the interactions and solubility of bovine pancreatic trypsin inhibitor. Biophys. J. 76:2716-2726 (1999).
98. B. Guo, S. Kao, H. McDonald, A. Asanov, L. L. Combs, and W. W. Wilson. Correlation of second virial coefficients and solubilities useful in protein crystal growth. J. Cryst. Growth 196:424-433 (1999).
99. C. Haas, J. Drenth, and W. W. Wilson. Relation between the solubility of proteins in aqueous solutions and the second virial coefficient of the solution. J. Phys. Chem. B 103:2808-2811 (1999).
100. D. F. Rosenbaum and C. F. Zukoski. Protein interactions and crystallization. J. Cryst. Growth 169:752-758 (1996).
101. A. George and W. W. Wilson. Predicting protein crystallization from a dilute solution property. Acta Cryst. D50:361-365 (1994).
102. P. E. Pjura, A. M. Lenhoff, S. A. Leonard, and A. G. Gittis. Protein crystallization by desigh: Chymotrypsinogen without precipitants. J. Mol. Biol. 300:235-239 (2000).
103. O. D. Velev, E. W. Kaler, and A. M. Lenhoff. Protein interactions in solution characterized by light and neutron scattering: Comparison of lysozyme and chymotrypsinogen. Biophys. J. 75:2682-2697 (1998).
104. S. Krishnan, E. Y. Chi, S. J. Wood, B. S Kendrick, C. Li, W. Garzon-Rodriguez, J. Wypych, T. W. Randolph, L. O. Narhi, A. L. Biere, M. Citron, and J. F. Carpenter. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis. Biochemistry 42:829-837 (2002).
105. D. Hamada and C. M. Dobson. A kinetic study of beta-lactoglobulin amyloid fibril formation promoted by urea. Protein Sci. 11:2417-2426 (2002).
106. J. H. Come, P. E. Fraser, and P. T. Lansbury. A kinetic-model for amyloid formation in the prion diseases - importance of seeding. Proc. Natl. Acad. Sci. USA 90:5959-5963 (1993).
107. J. Zurdo, J. I. Guijarro, J. L. Jimenez, H. R. Saibil, and C. M. Dobson. Dependence on solution conditions of aggregation and amyloid formation by an sh3 domain. J. Mol. Biol. 311:325-340 (2001).
108. S. M. Chen, V. Berthelier, J. B. Hamilton, B. O'Nuallain, and R. Wetzel. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochem. 41:7391-7399 (2002).
109. P. G. Debenedetti. Metastable Liquids: Concepts and Principles, Princeton University Press, Princeton, 1996.
110. A. D. Randolph and M. A. Larson. Theory of Particulate Processes: Analysis and Techniques of Continuous Crystallization, Academic Press Inc., San Diego, California, 1988.
111. H. Naiki and F. Gejyo. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 309:305-318 (1999).